<DOC>
	<DOCNO>NCT01981486</DOCNO>
	<brief_summary>PF-05180999 novel phosphodiesterase-2 ( PDE2 ) inhibitor . The purpose study evaluate safety , tolerability , pharmacokinetics multiple dos PF-05180999 administer twice daily 14 day . Exploratory measure PDE2 inhibition also evaluate blood blister fluid .</brief_summary>
	<brief_title>A Study Of The Safety , Tolerability , And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Healthy male and/or female ( nonchildbearing potential ) subject age 18 55 year Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Subjects Gilbert 's disease screen laboratory test result deviate upper and/or lower limit reference acceptable range . The exception liver function test must exceed upper limit normal . Subjects evidence , history , hepatic disorder , include acute chronic hepatitis B hepatitis C. Subjects light skin dark skin ( discretion investigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>PF-05180999</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>migraine</keyword>
	<keyword>PDE2</keyword>
	<keyword>cAMP</keyword>
	<keyword>cGMP</keyword>
	<keyword>cantharidin</keyword>
	<keyword>blister</keyword>
	<keyword>CYP3A induction</keyword>
</DOC>